Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 35 GATEHOUSE DRIVE A2 WALTHAM MA 02451 |
Tel: | N/A |
Website: | https://morphictx.com |
IR: | See website |
Key People | ||
Bruce N. Rogers President | Praveen P. Tipirneni Chief Executive Officer, Director | Marc Schegerin Chief Financial Officer, Chief Operating Officer |
Robert E. Farrell Senior Vice President - Finance, Chief Accounting Officer | William David DeVaul General Counsel, Secretary |
Business Overview |
Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company's Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications. |
Financial Overview |
For the fiscal year ended 31 December 2023, Morphic Holding Inc revenues decreased 99% to $521K. Net loss increased from $59M to $152.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - B increase of 36% to $120.8M (expense), Stock-based Compensation in R&D increase of 45% to $19.6M (expense). |
Employees: | 121 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $672.18M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.52M as of Dec 31, 2023 |
EBITDA (TTM): | -$177.60M as of Dec 31, 2023 |
Net annual income (TTM): | -$152.10M as of Dec 31, 2023 |
Free cash flow (TTM): | -$113.55M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 50,037,229 as of Feb 20, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |